Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Reports Strong Q4 Revenue Growth Amid Swelling Losses

NEW YORK, Aug. 21 - Myriad Genetics today reported strong fourth-quarter revenue growth, a surge in R&D spending, and a ballooning net loss.

 

For the period ended June 30 the company posted $14.1 million in total receipts compared with $10.8 million for the same time one year ago.

 

R&D spending echoed every other cost center and grew in the current fourth quarter to $10.7 million from $7.2 million in the same period 2001, Myriad said.

 

As a result, fourth-quarter net loss swelled to $6.8 million, or $.29 per share, from $2.2 million, or $.09 per share, year over year, according to the company.

 

Myriad said it had about $124.2 million in cash and investments as of June 30.

 

Click here for more information.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.